L-carnitine in patients with ischemic cardiomyopathy heart failure, the application of performance evaluation
Objective: to study the in patients with ischemic cardiomyopathy heart failure for application of the clinical effect of l-carnitine. Methods: 2011 cases in our hospital from 2011 to 2013 in patients with ischemic cardiomyopathy heart failure with random number table method group, 32 cases in each group, wil be the implementation of anti platelet aggregation, against myocardial ischemia, diuretic and angiotensin transferase inhibitors such as routine treatment as control group, would impose l-carnitine treatment under the premise set as observation group, assess the treatment outcome of the two groups, summarize the treatment experience. Results: the observation group after treatment, the clinical efficacy of 93.8%can be obtained, compared with 68.8% in the control group, significant difference (P < 0.05). After treatment, the observation group in the left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD) and cardiac output (CO), cardiac ultrasound indicators compared with before treatment, control group improved significantly (P < 0.05). Conclusion: l-carnitine for patients with ischemic cardiomyopathy heart failure treatment, can guarantee the clinical curative effect, help improve patient, is the key to future clinical improve the level of the disease treatment, advice.
NETL
NSTL
万方数据
